Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Boceprevir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Scientists Identified GC376 and Boceprevir Can Inhibit SARS-Co V-2
Details : Boceprevir and GC376, can inhibit the enzymatic activity well from 18 chemical drugs by in vitro fluorescence resonance energy transfer (FRET) enzymatic assays.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 14, 2020
Lead Product(s) : Boceprevir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?